Therapeutic peptides: current applications and future directions

L Wang, N Wang, W Zhang, X Cheng, Z Yan… - Signal transduction and …, 2022 - nature.com
Peptide drug development has made great progress in the last decade thanks to new
production, modification, and analytic technologies. Peptides have been produced and …

SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants

D Martínez-Flores, J Zepeda-Cervantes… - Frontiers in …, 2021 - frontiersin.org
Coronavirus 19 Disease (COVID-19) originating in the province of Wuhan, China in 2019, is
caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), whose …

Determinants of COVID-19 vaccine acceptance in Saudi Arabia: a web-based national survey

M Al-Mohaithef, BK Padhi - Journal of multidisciplinary healthcare, 2020 - Taylor & Francis
Background Vaccine hesitancy is a potential threat to global public health. Since there is an
unprecedented global effort to develop a vaccine against the COVID-19 pandemic, much …

Vaccines for COVID-19

JS Tregoning, ES Brown… - Clinical & …, 2020 - academic.oup.com
Since the emergence of COVID-19, caused by the SARS-CoV-2 virus at the end of 2019,
there has been an explosion of vaccine development. By 24 September 2020, a staggering …

In silico studies on the comparative characterization of the interactions of SARS‐CoV‐2 spike glycoprotein with ACE‐2 receptor homologs and human TLRs

A Choudhury, S Mukherjee - Journal of medical virology, 2020 - Wiley Online Library
Abstract Coronavirus disease‐2019 (COVID‐19) outbreak due to novel coronavirus or
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection has come out as …

Mesenchymal stem cell therapy for COVID-19: present or future

A Golchin, E Seyedjafari, A Ardeshirylajimi - Stem cell reviews and reports, 2020 - Springer
Abstract “COVID-19” is the word that certainly isn't forgotten by everybody who lives in the
first half of the twenty-first century. COVID-19, as a pandemic, has led many researchers …

COVID-19 vaccine: where are we now and where should we go?

S Soleimanpour, A Yaghoubi - Expert review of vaccines, 2021 - Taylor & Francis
Introduction The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has
currently caused the pandemic with a high progressive speed and has been considered as …

Artificial intelligence for COVID-19 drug discovery and vaccine development

A Keshavarzi Arshadi, J Webb, M Salem… - Frontiers in Artificial …, 2020 - frontiersin.org
SARS-COV-2 has roused the scientific community with a call to action to combat the growing
pandemic. At the time of this writing, there are as yet no novel antiviral agents or approved …

[HTML][HTML] Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection

A Rahimi, A Mirzazadeh, S Tavakolpour - Genomics, 2021 - Elsevier
The outbreak of 2019-novel coronavirus disease (COVID-19), caused by SARS-CoV-2,
started in late 2019; in a short time, it has spread rapidly all over the world. Although some …

COVID-19 and SARS-CoV-2. Modeling the present, looking at the future

E Estrada - Physics reports, 2020 - Elsevier
Abstract Since December 2019 the Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) has produced an outbreak of pulmonary disease which has soon become a …